CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9) is a revolutionary genome editing technology that enables precise modification of DNA sequences within living organisms. Originally derived from the bacterial immune system, CRISPR-Cas9 allows researchers to selectively target and edit specific genes by utilizing RNA molecules to guide the Cas9 protein to the desired genomic location. This technology has transformed genetic research, offering unprecedented accuracy, efficiency, and simplicity in gene editing. CRISPR-Cas9 has diverse applications, ranging from basic scientific research to potential therapeutic interventions for genetic disorders. In research, it allows the investigation of gene function, regulation, and the study of diseases with a genetic basis. Moreover, CRISPR-Cas9 holds promise in developing novel treatments for genetic conditions by correcting or modifying defective genes. The versatility of CRISPR-Cas9 extends to agriculture, where it can be employed to enhance crop traits or develop disease-resistant plants. While CRISPR-Cas9 offers remarkable opportunities, ethical considerations surround its use, particularly in human germline editing. The ability to edit the human germline raises ethical questions about unintended consequences and the potential for designer babies. Scientists and ethicists continue to engage in discussions to establish responsible guidelines for the application of CRISPR-Cas9. In summary, CRISPR-Cas9 represents a groundbreaking tool in genetic engineering, offering unprecedented precision in gene editing with transformative implications for biological research, medicine, and agriculture. Ongoing advancements and ethical considerations will shape the responsible and beneficial application of this revolutionary technology.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Stem cell technologies to integrate biodesign related tissue engineering within the frame of cell based regenerative medicine: towards the preventive therapeutic and rehabilitative resources and benefits
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : In vitro evaluation of lyophilized Dedifferentiated Fat cells (DFAT) impregnated artificial dermis
Kazutaka Soejima, Nihon University, School of Medicine, Japan
Title :
Nagy Habib, Imperial College London, United Kingdom
Title :
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : The regenerative medicine of the future
Marco Polettini, DVM, Italy